GKOS
GLAUKOS Corp
NYSE · Healthcare · Medical - Devices · US
$164.84
−0.46%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$166.08
From 52W high−13.04%
Volume985415.00
Market cap$9.72B
P/E (TTM)—
P/S (TTM)15.9x
Div yield—
Key dataOct 16, 2026
Open
$166.08
From 52W high
−13.04%
Volume
985415.00
Market cap
$9.72B
ValuationView details →
P/E (Fwd)
440.2x
EV/EBITDA
−67.7x
P/E (TTM)
—
RSI (14)
48.5
MomentumView details →
1D Return
−0.46%
YTD Return
+45.74%
SummaryUpdated Jun 1, 2026
Glaukos Corporation (NASDAQ:GKOS) is a specialized ophthalmic medical technology and pharmaceutical company founded in 1998 and headquartered in San Clemente, California. The company went public in June 2015 and has established itself as a pioneer in minimally invasive glaucoma surgery (MIGS) and innovative ocular therapeutics. Glaukos focuses on developing and commercializing novel therapies for treating glaucoma, corneal disorders, and retinal diseases, with a particular emphasis on what it calls "interventional glaucoma" - a proactive approach to treating eye pressure and preventing vision loss before significant damage occurs.
Similar companies
Latest newsMore news →
GLAUKOS Corp shares declined 6.3% following the licensing news.7d agoGLAUKOS Corp reported successful topline outcomes from its latest Phase 4 clinical study of a novel eye therapy, describing superior intraocular pressure reduction.7d agoGlaukos announced positive topline results from its Phase 4 GLK-101-04 trial evaluating iDose TR with cataract surgery versus cataract surgery alone in patients with open-angle glaucoma.7d ago